Lupus patients are not getting sick from CCP virus

[Buy1Sell2]

No one said that Lupus patients don't contract CCP virus. Rather, what was said was that Lupus patients are not getting sick from CCP virus.

 

[Dr. Love]

"Lupus patients are not getting sick from CCP virus"

It is time that we started calling out dangerous and incorrect medical bullshiat directly.

There Is No Study Proving That ‘Lupus Patients Don’t Get Coronavirus’ Because They Take Hydroxychloroquine
Rumors are circulating about a study that shows people with lupus don’t get COVID-19, but emerging data says otherwise.

You may have seen recent headlines suggesting that people with lupus, an autoimmune disease that affects about 1.5 million Americans, don’t contract coronavirus because many of them take hydroxychloroquine. This information is not true, and the Global Healthy Living Foundation needs to set the record straight based on data and medical expertise.

Hydroxychloroquine — a first-line lupus therapy that is also commonly used to treat rheumatoid arthritis and other rheumatologic conditions — is currently being studied as a potential treatment for COVID-19 because of its anti-viral properties. But there is no conclusive evidence of its benefits for coronavirus yet.

During a White House briefing Saturday April 4, President Trump suggested there was research showing that lupus patients did not get coronavirus. The implication was that perhaps taking hydroxychloroquine was protecting them.

“They should look at the lupus thing. I don’t know what it says, but there’s a rumor out there that because it takes care of lupus very effectively as I understand it, and it’s a, you know, a drug that’s used for lupus,” President Trump said during the briefing. “So there’s a study out there that says people that have lupus haven’t been catching this virus. Maybe it’s true, maybe it’s not.”

It is not true.

Emerging Data on Lupus Patients and COVID-19
A couple of weeks ago, as the coronavirus pandemic was massively increasing in scale and impact, rheumatology researchers from around the globe started collaborating to collect data on patients with such conditions as lupus to answer questions exactly like this. Do patients with autoimmune conditions fare differently from COVID-19 than the general population? Do certain medications lead to better or worse outcomes?

The registry is called the COVID-19 Global Rheumatology Alliance. (The Global Healthy Living Foundation and its arthritis patient community CreakyJoints was one of its first members and advisers.) More data is being collected daily and certainly it is too early to make any definitive conclusions about COVID-19 in rheumatology patients, but the data so far show that:

1. Lupus patients do, in fact, get COVID-19.
2. Many of them are taking hydroxychloroquine at the time of their diagnosis.

According to information from the registry shared over the last few days on Twitter, the registry now has data on 110 patients. Most patients have rheumatoid arthritis (36 percent), followed by psoriatic arthritis and lupus (17 percent each).

On April 2 — two days before the President’s recent statements about lupus and hydroxychloroquine — the registry Tweeted: “One frequently asked question: Over 25% of patients who developed a COVID-19 were on HCQ [hydroxychloroquine] at the time of diagnosis.”

Last night, the registry tweeted: “Based on early data currently available in our registry, we are not able to report any evidence of a protective effect from hydroxychloroquine against COVID-19. A randomized, controlled trial would be the only way to study this to get a reliable answer to this question.”

Rheumatologists who treat patients with lupus are concerned about rumors suggesting patients are less susceptible to COVID-19.

Misinformation like this puts patients at risk, says rheumatologist Grace C. Wright, MD, PhD, founder and president of the Association of Women in Rheumatology (AWIR). “There is no data that hydroxychloroquine is protective against contracting COVID-19.” She, and many other rheumatologists the Global Healthy Living Foundation has spoken with over the last several days and weeks, worry that it could be a serious issue if people who take hydroxychloroquine mistakenly think they are protected from infection.

Rheumatologist Robin K. Dore, MD, clinical professor of medicine at the David Geffen School of Medicine at UCLA, shared this message on her patient portal:

To Dr. Dore’s patients who are taking Plaquenil (hydroxychloroquine), there is no evidence that this medication prevents one from developing a COVID-19 infection. This medication is now being studied to determine if it lessens the severity of the infection once a person has developed the disease. Dr. Dore urges you to continue social distancing, hand washing, and wearing a face covering when you are out in the public. Do not feel that you are immune to the virus if you are taking Plaquenil. Further updates will follow as appropriate.

Concerns About Access to Hydroxychloroquine
Other parts of the White House briefing continued to exacerbate fears among lupus and other rheumatology patients about having access to hydroxychloroquine, which has been in short supply due to its current use as an experimental COVID-19 therapy.

President Trump urged Americans to take the medication: “What do you have to lose? Take it. I really think they should take it. But it’s their choice. And it’s their doctor’s choice or the doctors in the hospital. But hydroxychloroquine. Try it, if you’d like.”

Messages like these could further impact the availability of this crucial medication for people who take it every day to prevent complications from lupus and other conditions.

We have written before about how denying hydroxychloroquine prescriptions to rheumatology patients, which is occurring in the Kaiser Permanente health care system in California right now, for example, is dangerous and even life-threatening. We have also explained how hydroxychloroquine is used to treat lupus and other rheumatologic conditions. To reiterate some of those key points:

“If a patient has to stop taking hydroxychloroquine, they are more likely to experience a flare,” says Ashira Blazer, MD, a rheumatologist at NYU Langone Health in New York City whose clinical research focuses on lupus. “And the last thing we want is for patients not to be able to take a drug that is helping them, then flare, then require heavier immunosuppressing drugs, then be more immunocompromised, and then contract COVID-19.”

“Hydroxychloroquine is a safe, effective, and inexpensive therapy for conditions like lupus and rheumatoid arthritis,” says Dr. Blazer. “If there is a big shortage, it will exacerbate health disparities. People who need an effective and affordable drug won’t be able to get it. There is a risk of mortality, especially for minority women who are disproportionately affected by serious lupus complications, if hydroxychloroquine is not made available to our most vulnerable patients.”

There are a bunch of people calling the data from this Alliance reports bullshit.
Do you have any other sources?

 

[Bugenhagen]

There are a bunch of people calling the data from this Alliance reports bullshit.
Do you have any other sources?

You are messing with GWB here man, stating something like that as a fact with no source? Watch the master school you..

 

[gwb-trading]

There are a bunch of people calling the data from this Alliance reports bullshit.
Do you have any other sources?

Why don't you contact all the founders of the alliance listed below -- many who are viewed as some of the top medical experts in the world -- and tell them that their COVID–19 Global Rheumatology Alliance is bullshit.

https://rheum-covid.org/about/
About

Establishing The COVID–19 Global Rheumatology Alliance Steering Committee:

The steering committee is composed of academic and community rheumatologists and a patient representative. The steering committee was formed with the goal of rapidly curating and disseminating accurate, timely, evidence-based information to the community of rheumatology providers and patients.

Please note that we are a very early stage, grassroots organization (established March 12, 2020) that was rapidly formed in response to the global COVID–19 pandemic. Listed below is the initial Steering Committee. Representation based on gender, geographic location, and ethnic diversity is very important to our group, and will be an important focus as we continue to grow and evolve.

Current Steering Committee:

Philip Robinson, MBChB, PhD, FRACP, MAICD (@philipcrobinson)
Chair, Governance, Policy
Dr. Philip Robinson is a clinical and academic rheumatologist at the Royal Brisbane Hospital, in Queensland, Australia and associate professor at the Faculty of Medicine at The University of Queensland.

Jinoos Yazdany, M.D., MPH (@JYazdanyMD)
Vice-Chair, Real-world Data Infrastructure, Registry and IRB/Ethics
Dr. Jinoos Yazdany is Chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital (ZSFG) and the Alice Betts Endowed Professor of Medicine at the University of California, San Francisco (UCSF). She practices rheumatology at ZSFG and co-directs the Lupus Clinic at UCSF Health.

Paul Sufka, M.D. (@psufka)
Technology and Marketing Lead
Dr. Paul Sufka is department chair and practices rheumatology with HealthPartners medical group in St. Paul, MN. He is also the social media editor for Arthritis & Rheumatology, Arthritis Care & Research, and ACR Open Rheumatology.

Rebecca Grainger, MBChB (Dstn), BMedSci (Dstn) MIsntD, CHIA, FRACP, FACHI, PhD (@Drbeckyg)
Literature Review Co-Lead
Dr. Rebecca Grainger is a clinical and academic rheumatologist in New Zealand, working in public hospital practice [Hutt VAlled DHB]. She is an Associate Professor in the Department of Medicine and Department of Pathology and Molecular Medicine at the University of Otago in New Zealand.

Zach Wallace, M.D., MSc (@zach_wallace_md)
Literature Review Co-Lead
Dr. Zachary Wallace is a rheumatologist and researcher in the Rheumatology Unit and Clinical Epidemiology Program at Massachusetts General Hospital. He is an Assistant Professor of Medicine at Harvard Medical School.

Suleman Bhana, M.D., FACR (@DrBhana)
Organizational Liaison and Media
Dr. Suleman Bhana is a clinical Rheumatologist in a multi-specialty group private practice in New York. He is chair of the Communications and Marketing Committee of the American College of Rheumatology, a co-found of the #RheumJC twitter based journal club, and former co-host of The Rheumatology Podcast.

Emily Sirotich (@emilysirotich)
Patient Engagement Co-Lead
Emily Sirotich is a patient partner, board member of the Canadian Arthritis Patient Alliance, and PhD student in Health Research Methodology at McMaster University.

Jean Liew, M. D, (@rheum_cat)
Administrative Lead
Dr. Jean Liew is a rheumatology fellow at the University of Washington in Seattle, WA, where she performs clinical research.

Jonathan Hausmann, M.D. (@hausmannMD)
Patient Registries Collaboration Lead
Jonathan S. Hausmann is a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center at Harvard Medical School.

Pedro Machado, M.D. (@pedrommcmachado)
European Lead
Dr. Pedro Machado is an Associate Professor & Consultant Rheumatologist at University College London (UCL). He leads a myositis clinic at University College London Hospitals (UCLH) and an axial spondyloarthritis clinic at Northwick Park Hospital. He is the Chair of the EULAR Standing Committee on Epidemiology and Health Services Research (SCEHSR) and a member of the EULAR Executive Committee.

Wendy Costello (@wendycostello2)
Patient Engagement Co-Lead
Wendy Costello is a mum to Niamh who was diagnosed at the age of 3 with Juvenile Idiopathic Arthritis. She is the co-founder and chairperson of the Irish Children’s Arthritis Network (iCAN) in 2013, which is a volunteer charity that supports children and young people living with paediatric rheumatic diseases. She is also the current Chair of the European Network of Children with Arthritis (ENCA), sits on the board of the Paediatric Rheumatology European Society council, and is chair of the steering committee of the University College Dublin Centre of Arthritis Research.

Current Regional Leads:

Country or Region Name of Lead Institution or Affiliation
Australia David Liew Austin Health/University of Melbourne
Austria Paul Studenic Medical University of Vienna
Brazil Claudia Marques Universidade Federal de Pernambuco/Brazilian Society of Rheumatology
Canada Diane LaCaille University of British Columbia

Sindhu Johnson University Health Network

Keshini Devakandan University Health Network

Carter Thorne University of Toronto
China Mengtao Li Chinese SLE Treatment and Research Group (CSTAR)
Colombia Sebastian Herrera Hospital General de Medellín / ARTMEDICA / Universidad CES
France Laure Gossec Sorbonne Université

Francis Berenbaum Sorbonne Université, INSERM, AP-HP
Germany Anja Strangfeld Deutsches Rheuma-Forschungszentrum Berlin (DRFZ) – Ein Institut der Leibniz-Gemeinschaft

Johannes Knitza Universitätsklinikum Erlangen

Peter Korsten Universitätsmedizin Göttingen
Ireland Richard Conway St. James’s Hospital / Blackrock Clinic
Japan Mari Kihara Pharmaceuticals and Medical Devices Agency, Tokyo Medical and Dental University
Latvia Bulina Inita Pauls Stradins Clinicak University Hospital
Mexico Erick Adrian Zamora Tehozol Centro Médico Pensiones
Peru Manuel Ugarte-Gil Universidad Científica del Sur-Hospital Guillermo Almenara Irigoyen
Philippines Anna Kristina Gutierrez Makati Medical Center/ Philippine Rheumatology Association

Geraldine Zamora University of the Philippines-Philippine General Hospital/ St. Luke’s Medical Center
Portugal Elsa Mateus Portuguese League Against Rheumatic Diseases
Spain Loreto Carmona Instituto de Salud Musculoesquelética
Saudi Arabia Ibrahim Almaghlouth King Saud University
South Africa Kate Webb University of Cape Town

Kavita Makan University of Witwatersrand
Turkey Vedat Hamuryudan Istanbul University-Cerrahpasa, Cerrahpasa Medical School
UK Taryn Youngstein Imperial College London

Pedro Machado University College London

Richard Beesley Juvenile Arthritis Research & ENCA

Kimme Hyrich University of Manchester

Bethan Goulden University College Hospital London

Chris Wincup University College Hospital London

Coziana Ciurtin University College Hospital London

Jessica Manson University College Hospital London

Su-Ann Yeoh University College Hospital London
USA Adam Kilian George Washington University

Maria Danila University of Alabama at Birmingham

Isabelle Amigues National Jewish Health

Eugenia Chock Yale School of Medicine

Michael Putman Northwestern University

Laura Lewandowski National Institutes of Health

Jon Hausmann Boston Children’s /Beth Israel Deaconess Medical Center/ Harvard Medical School

Maximilian Konig Johns Hopkins University

Beth Wallace University of Michigan

Andrew Vreede University of Michigan/Ann Arbor VA

Reema Syed Washington University School of Medicine

Sebastian Sattui Hospital for Special Surgery (NY)

Arundathi Jayatilleke Temple University

Jean Liew University of Washington

Namrata Singh University of Washington

Aarat Patel University of Virginia

Katherine Wysham VA Puget Sound/University of Washington

Alí Duarte Mayo Clinic

Marc Nolan HealthPartners (MN)

Jeffrey Sparks Brigham and Women’s Hospital/Harvard Medical School

Leanna Wise Keck Hospital of USC
About our current collaboration with the American College of Rheumatology (ACR):

To facilitate our ability to quickly address the challenges facing rheumatology in the context of this pandemic, we are pursuing a collaboration with the American College of Rheumatology (ACR) to support our initial development as an organization. This arrangement will allow us to leverage the rich resources and support of the ACR so that we can ultimately form an independent organization. As we develop “in-house” expertise in such topics as regulatory compliance, finance, and grant management, the ACR can help us meet our obligations and responsibilities to the community that The COVID-19 Global Rheumatology Alliance serves. Both The COVID-19 Global Rheumatology Alliance and ACR agree that the ultimate goal is for The COVID-19 Global Rheumatology Alliance to be an independent organization pursuing its mission.

Our Mission:

Our mission is to create a secure, de-identified, international case reporting registry and curate and disseminate the outputs from that registry. It is our hope that the information collected will help guide rheumatology clinicians in assessing and treating patients with rheumatologic disease and in evaluating the risk of infection in patients on immunosuppression.

Our data sharing agreement with other groups and organizations:

We established The COVID–19 Global Rheumatology Alliance’s registries during the time of a global crisis, for the betterment of all people. Our goal is to provide an open platform for data collection, sharing, and dissemination which is transparent, inclusive, and non-competitive in the most democratic and responsible ways possible.

In partnering with The COVID–19 Global Rheumatology Alliance, you agree to share collective data with the above purpose in mind. In return, you will receive access to the collected data that is to be used for the betterment of society. Any data-sharing agreements are subject to institutional review board approval.

 

[gwb-trading]

You are messing with GWB here man, stating something like that as a fact with no source? Watch the master school you..

This is the typical situation where someone has no evidence to support their assertions and they just cast aspersions on creditable, factual sources..... rather then presenting real information.

 

[Bugenhagen]

No one said that Lupus patients don't contract CCP virus. Rather, what was said was that Lupus patients are not getting sick from CCP virus.

And this is nothing to with a dozen other factors even if true? Like not having a normal immune system to react to it in a damaging manner? As appears to be happening to many healthy adults with no prior conditions and covid'19

https://www.cidrap.umn.edu/news-perspective/2013/08/study-shows-cytokine-storm-fatal-2009-h1n1-cases

How was Lupus with H1N1 and how long do lupus patients live? Coz you know, many can now live a long life nowadays but still many die younger so fewer elderly to snuff it.

 

[Buy1Sell2]

If you are an idiot, please do not post in this thread. Shartfartandrunfast equals Idiot.

 

[Dr. Love]

Why don't you contact all the founders of the alliance listed below -- many who are viewed as some of the top medical experts in the world -- and tell them that their COVID–19 Global Rheumatology Alliance is bullshit.

https://rheum-covid.org/about/
About

Establishing The COVID–19 Global Rheumatology Alliance Steering Committee:

The steering committee is composed of academic and community rheumatologists and a patient representative. The steering committee was formed with the goal of rapidly curating and disseminating accurate, timely, evidence-based information to the community of rheumatology providers and patients.

Please note that we are a very early stage, grassroots organization (established March 12, 2020) that was rapidly formed in response to the global COVID–19 pandemic. Listed below is the initial Steering Committee. Representation based on gender, geographic location, and ethnic diversity is very important to our group, and will be an important focus as we continue to grow and evolve.

Current Steering Committee:

Philip Robinson, MBChB, PhD, FRACP, MAICD (@philipcrobinson)
Chair, Governance, Policy
Dr. Philip Robinson is a clinical and academic rheumatologist at the Royal Brisbane Hospital, in Queensland, Australia and associate professor at the Faculty of Medicine at The University of Queensland.

Jinoos Yazdany, M.D., MPH (@JYazdanyMD)
Vice-Chair, Real-world Data Infrastructure, Registry and IRB/Ethics
Dr. Jinoos Yazdany is Chief of the Division of Rheumatology at Zuckerberg San Francisco General Hospital (ZSFG) and the Alice Betts Endowed Professor of Medicine at the University of California, San Francisco (UCSF). She practices rheumatology at ZSFG and co-directs the Lupus Clinic at UCSF Health.

Paul Sufka, M.D. (@psufka)
Technology and Marketing Lead
Dr. Paul Sufka is department chair and practices rheumatology with HealthPartners medical group in St. Paul, MN. He is also the social media editor for Arthritis & Rheumatology, Arthritis Care & Research, and ACR Open Rheumatology.

Rebecca Grainger, MBChB (Dstn), BMedSci (Dstn) MIsntD, CHIA, FRACP, FACHI, PhD (@Drbeckyg)
Literature Review Co-Lead
Dr. Rebecca Grainger is a clinical and academic rheumatologist in New Zealand, working in public hospital practice [Hutt VAlled DHB]. She is an Associate Professor in the Department of Medicine and Department of Pathology and Molecular Medicine at the University of Otago in New Zealand.

Zach Wallace, M.D., MSc (@zach_wallace_md)
Literature Review Co-Lead
Dr. Zachary Wallace is a rheumatologist and researcher in the Rheumatology Unit and Clinical Epidemiology Program at Massachusetts General Hospital. He is an Assistant Professor of Medicine at Harvard Medical School.

Suleman Bhana, M.D., FACR (@DrBhana)
Organizational Liaison and Media
Dr. Suleman Bhana is a clinical Rheumatologist in a multi-specialty group private practice in New York. He is chair of the Communications and Marketing Committee of the American College of Rheumatology, a co-found of the #RheumJC twitter based journal club, and former co-host of The Rheumatology Podcast.

Emily Sirotich (@emilysirotich)
Patient Engagement Co-Lead
Emily Sirotich is a patient partner, board member of the Canadian Arthritis Patient Alliance, and PhD student in Health Research Methodology at McMaster University.

Jean Liew, M. D, (@rheum_cat)
Administrative Lead
Dr. Jean Liew is a rheumatology fellow at the University of Washington in Seattle, WA, where she performs clinical research.

Jonathan Hausmann, M.D. (@hausmannMD)
Patient Registries Collaboration Lead
Jonathan S. Hausmann is a pediatric and adult rheumatologist at Boston Children’s Hospital and Beth Israel Deaconess Medical Center at Harvard Medical School.

Pedro Machado, M.D. (@pedrommcmachado)
European Lead
Dr. Pedro Machado is an Associate Professor & Consultant Rheumatologist at University College London (UCL). He leads a myositis clinic at University College London Hospitals (UCLH) and an axial spondyloarthritis clinic at Northwick Park Hospital. He is the Chair of the EULAR Standing Committee on Epidemiology and Health Services Research (SCEHSR) and a member of the EULAR Executive Committee.

Wendy Costello (@wendycostello2)
Patient Engagement Co-Lead
Wendy Costello is a mum to Niamh who was diagnosed at the age of 3 with Juvenile Idiopathic Arthritis. She is the co-founder and chairperson of the Irish Children’s Arthritis Network (iCAN) in 2013, which is a volunteer charity that supports children and young people living with paediatric rheumatic diseases. She is also the current Chair of the European Network of Children with Arthritis (ENCA), sits on the board of the Paediatric Rheumatology European Society council, and is chair of the steering committee of the University College Dublin Centre of Arthritis Research.

Current Regional Leads:

Country or Region Name of Lead Institution or Affiliation
Australia David Liew Austin Health/University of Melbourne
Austria Paul Studenic Medical University of Vienna
Brazil Claudia Marques Universidade Federal de Pernambuco/Brazilian Society of Rheumatology
Canada Diane LaCaille University of British Columbia

Sindhu Johnson University Health Network

Keshini Devakandan University Health Network

Carter Thorne University of Toronto
China Mengtao Li Chinese SLE Treatment and Research Group (CSTAR)
Colombia Sebastian Herrera Hospital General de Medellín / ARTMEDICA / Universidad CES
France Laure Gossec Sorbonne Université

Francis Berenbaum Sorbonne Université, INSERM, AP-HP
Germany Anja Strangfeld Deutsches Rheuma-Forschungszentrum Berlin (DRFZ) – Ein Institut der Leibniz-Gemeinschaft

Johannes Knitza Universitätsklinikum Erlangen

Peter Korsten Universitätsmedizin Göttingen
Ireland Richard Conway St. James’s Hospital / Blackrock Clinic
Japan Mari Kihara Pharmaceuticals and Medical Devices Agency, Tokyo Medical and Dental University
Latvia Bulina Inita Pauls Stradins Clinicak University Hospital
Mexico Erick Adrian Zamora Tehozol Centro Médico Pensiones
Peru Manuel Ugarte-Gil Universidad Científica del Sur-Hospital Guillermo Almenara Irigoyen
Philippines Anna Kristina Gutierrez Makati Medical Center/ Philippine Rheumatology Association

Geraldine Zamora University of the Philippines-Philippine General Hospital/ St. Luke’s Medical Center
Portugal Elsa Mateus Portuguese League Against Rheumatic Diseases
Spain Loreto Carmona Instituto de Salud Musculoesquelética
Saudi Arabia Ibrahim Almaghlouth King Saud University
South Africa Kate Webb University of Cape Town

Kavita Makan University of Witwatersrand
Turkey Vedat Hamuryudan Istanbul University-Cerrahpasa, Cerrahpasa Medical School
UK Taryn Youngstein Imperial College London

Pedro Machado University College London

Richard Beesley Juvenile Arthritis Research & ENCA

Kimme Hyrich University of Manchester

Bethan Goulden University College Hospital London

Chris Wincup University College Hospital London

Coziana Ciurtin University College Hospital London

Jessica Manson University College Hospital London

Su-Ann Yeoh University College Hospital London
USA Adam Kilian George Washington University

Maria Danila University of Alabama at Birmingham

Isabelle Amigues National Jewish Health

Eugenia Chock Yale School of Medicine

Michael Putman Northwestern University

Laura Lewandowski National Institutes of Health

Jon Hausmann Boston Children’s /Beth Israel Deaconess Medical Center/ Harvard Medical School

Maximilian Konig Johns Hopkins University

Beth Wallace University of Michigan

Andrew Vreede University of Michigan/Ann Arbor VA

Reema Syed Washington University School of Medicine

Sebastian Sattui Hospital for Special Surgery (NY)

Arundathi Jayatilleke Temple University

Jean Liew University of Washington

Namrata Singh University of Washington

Aarat Patel University of Virginia

Katherine Wysham VA Puget Sound/University of Washington

Alí Duarte Mayo Clinic

Marc Nolan HealthPartners (MN)

Jeffrey Sparks Brigham and Women’s Hospital/Harvard Medical School

Leanna Wise Keck Hospital of USC
About our current collaboration with the American College of Rheumatology (ACR):

To facilitate our ability to quickly address the challenges facing rheumatology in the context of this pandemic, we are pursuing a collaboration with the American College of Rheumatology (ACR) to support our initial development as an organization. This arrangement will allow us to leverage the rich resources and support of the ACR so that we can ultimately form an independent organization. As we develop “in-house” expertise in such topics as regulatory compliance, finance, and grant management, the ACR can help us meet our obligations and responsibilities to the community that The COVID-19 Global Rheumatology Alliance serves. Both The COVID-19 Global Rheumatology Alliance and ACR agree that the ultimate goal is for The COVID-19 Global Rheumatology Alliance to be an independent organization pursuing its mission.

Our Mission:

Our mission is to create a secure, de-identified, international case reporting registry and curate and disseminate the outputs from that registry. It is our hope that the information collected will help guide rheumatology clinicians in assessing and treating patients with rheumatologic disease and in evaluating the risk of infection in patients on immunosuppression.

Our data sharing agreement with other groups and organizations:

We established The COVID–19 Global Rheumatology Alliance’s registries during the time of a global crisis, for the betterment of all people. Our goal is to provide an open platform for data collection, sharing, and dissemination which is transparent, inclusive, and non-competitive in the most democratic and responsible ways possible.

In partnering with The COVID–19 Global Rheumatology Alliance, you agree to share collective data with the above purpose in mind. In return, you will receive access to the collected data that is to be used for the betterment of society. Any data-sharing agreements are subject to institutional review board approval.

Because probably they are suffering from TDS?

 

[gwb-trading]

No one said that Lupus patients don't contract CCP virus. Rather, what was said was that Lupus patients are not getting sick from CCP virus.

There are numerous articles all over the internet citing Lupus patients dying from COVID-19
Go do a simple google search and educate yourself.
--------------------------------------------------------------------------------------------------------------------------------

Brian Joseph is no stranger to death. But life as a funeral director and a person living with lupus during the COVID-19 pandemic has given him pause. Mortuary services are considered critical services exempt from the shelter-in-place declarations designed to slow the spread of the disease. And recently the calls to his five funeral home locations in southeast Michigan have increased.

“We’re in a hotspot in Detroit,” says Joseph. “We have four immediate burials today and three of them were COVID patients.” As a result, the homes have taken measures to protect both families and staff and to offer care to the best of their ability in an era of social distancing.

The fact that some of those victims had the same underlying condition he has is not lost on him. “I’ve seen lupus patients that are dying. On the death certificate it says cause of death: respiratory failure or COVID-19 and other significant factors: lupus or diabetes or SLE,” he says. “Does that not force me to step back and look? This is where my faith comes in. It tells me strongly to inhale and do everything that the scientists say.”

https://healthblog.uofmhealth.org/wellness-prevention/pandemic-fight-over-plaquenil

 

[Dr. Love]

This is the typical situation where someone has no evidence to support their assertions and they just cast aspersions on creditable, factual sources..... rather then presenting real information.

Haha. I am asking for evidence and you post stuff from Twitter. Ok, don't let me stop you.